source
- TriGemX Bio to go public via SPAC to advance migraine drug candidateTriGemX Bio, formerly known as Kallyope, said it will become a public company by merging with a special purpose acquisition company. The transaction is aimed at raising capital and accelerating the…
- Experts tout amylin as promising, potentially gentler obesity target as new combo therapies near FDA reviewWhile GLP-1 medicines dominate the weight‑loss market, some observers argue that amylin would have been the logical primary target for obesity treatment a decade ago. Novo Nordisk’s amylin/GLP‑1 c…